Lots of FLT3i action in the first #AML session of the day! Some takeaways. THREAD #ASH20 #leusm
1)Git + chemo: Of pts achieving FLT3 mutational clearance, only ~30% achieve this with induction. Molecular MRD rates increase with consolidation. #HDAC matters. Also, only ~30% of pts transplanted...Do we see the end of allo for FLT3-ITD+ AML? I don’t know yet.
2)Dec/quiz+/-ven: 81% CRc (55% bridged to allo) with triplet in R/R FLT3-ITD+ AML. Myelosuppression manageable with lower dose quiz, 14d ven, D14 BM to eval marrow ablation.
3)Gilt/aza: 67% CRc rate (pretty close to AZA/ven ), DOR 10.4 months. No results from AZA vs gilt/aza randomization yet. Would you enroll a pt to AZA only arm? I don’t think I would.
4)Sequential FLT3 TKI therapy: No real surprises here. Response/survival with FLT3i drops with each successive line of tx. RR to combos is higher. 2nd gen TKI (quiz) > 1st gen (sorafenib), esp in 2nd line.
You can follow @SmithLabSF.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.